Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
Genes · 30.06.2025 · 16 (7) · 772
DOI: 10.3390/genes16070772 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 30.06.2025. Verfasst von Panagiotis Agisilaos Angelopoulos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Haemato-Oncology, University of Milan, 20122 Milan, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute.
Abstract (Originalsprache)
Epidermal growth factor receptor (EGFR) mutations occur in approximately 10–20% of Caucasian and up to 50% of Asian patients with oncogene-addicted non-small cell lung cancer (NSCLC). Most frequently, alterations include exon 19 deletions and exon 21 L858R mutations, which confer sensitivity to EGFR tyrosine kinase inhibitors (TKIs). In the last decade, the third-generation EGFR-TKI osimertinib has represented the first-line standard of care for EGFR-mutant NSCLC. However, the development of acquired mechanisms of resistance significantly impacts long-term outcomes and represents a major therapeutic challenge. The mesenchymal–epithelial transition (MET) gene amplification and MET protein overexpression have emerged as prominent EGFR-independent (off-target) resistance mechanisms, detected in approximately 25% of osimertinib-resistant NSCLC. Noteworthy, variability in diagnostic thresholds, which differ between fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS) platforms, complicates its interpretation and clinical applicability. To address MET-driven resistance, several therapeutic strategies have been explored, including MET-TKIs, antibody–drug conjugates (ADCs), and bispecific monoclonal antibodies, and dual EGFR/MET inhibition has emerged as the most promising strategy. In this context, the bispecific EGFR/MET antibody amivantamab has demonstrated encouraging efficacy, regardless of MET alterations. Furthermore, the combination of the ADC telisotuzumab vedotin and osimertinib has been associated with activity in EGFR-mutant, c-MET protein-overexpressing, osimertinib-resistant NSCLC. Of note, several novel agents and combinations are currently under clinical development. The success of these targeted approaches relies on tissue re-biopsy at progression and accurate molecular profiling. Yet, tumor heterogeneity and procedural limitations may challenge the feasibility of re-biopsy, making biomarker-agnostic strategies viable alternatives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Haemato-Oncology, University of Milan, 20122 Milan, Italy.
- Division of Thoracic Oncology, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
- Division of Early Drug Development, European Institute of Oncology, IRCCS, 20141 Milan, Italy.
ORCID-Profile: Antonio Passaro, Ilaria Attili, Pamela Trillo Aliaga, Gianluca Spitaleri, Ester Del Signore, Giuseppe Curigliano
Förderung
- Ministero della Salute
Zitieren
APA
Angelopoulos, P. A., Passaro, A., Attili, I., Trillo Aliaga, P., Corvaja, C., Spitaleri, G., Battaiotto, E., Del Signore, E., Curigliano, G., & de Marinis, F. (2025). Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer. Genes, 16(7), 772. https://doi.org/10.3390/genes16070772
Vancouver
Angelopoulos PA, Passaro A, Attili I, Trillo Aliaga P, Corvaja C, Spitaleri G, et al. Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer. Genes. 2025;16(7):772. doi:10.3390/genes16070772
BibTeX
@article{Angelopoulos2025,
author = {Angelopoulos, Panagiotis Agisilaos and Passaro, Antonio and Attili, Ilaria and Trillo Aliaga, Pamela and Corvaja, Carla and Spitaleri, Gianluca and Battaiotto, Elena and Del Signore, Ester and Curigliano, Giuseppe and de Marinis, Filippo},
title = {Management of MET-Driven Resistance to Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer},
journal = {Genes},
year = {2025},
volume = {16},
number = {7},
pages = {772},
doi = {10.3390/genes16070772}
}
EUVIMED